These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35538689)

  • 1. Chemical complementarity between immune receptor CDR3s and candidate cancer antigens correlating with reduced survival: evidence for outcome mitigation with corticosteroid treatments.
    Patel AR; Patel DN; Tu YN; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
    J Biomol Struct Dyn; 2023 Jul; 41(10):4632-4640. PubMed ID: 35538689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer.
    Chobrutskiy BI; Chobrutskiy A; Zaman S; Yeagley M; Huda TI; Blanck G
    Mol Immunol; 2021 Jul; 135():247-253. PubMed ID: 33933816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: multi-cancer analyses of associated survival rates.
    Chobrutskiy BI; Yeagley M; Diviney A; Zaman S; Gozlan EC; Tipping P; Koohestani DM; Roca AM; Blanck G
    Immunology; 2020 Apr; 159(4):373-383. PubMed ID: 31821535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delineation of a T-cell receptor CDR3-cancer mutanome aromaticity factor, assessable via blood samples, that facilitates the establishment of survival distinctions in bladder cancer.
    Waweru JW; Mwangi KW; Barker VR; Gozlan EC; Yeagley M; Blanck G; Makokha FW
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4359-4366. PubMed ID: 36098856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival.
    Zaman S; Gorelick FS; Chrobrutskiy A; Chobrutskiy BI; Desir GV; Blanck G
    Oncotarget; 2024 Aug; 15():550-561. PubMed ID: 39102218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood-based T cell receptor anti-viral CDR3s are associated with worse overall survival for neuroblastoma.
    Kacsoh DB; Diaz MJ; Gozlan EC; Sahoo A; Song JJ; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):12047-12056. PubMed ID: 37421457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical Complementarity of Tumor Resident, Adaptive Immune Receptor CDR3s and Previously Defined Hepatitis C Virus Epitopes Correlates with Improved Outcomes in Hepatocellular Carcinoma.
    Song JJ; Chobrutskiy A; Chobrutskiy BI; Cios KJ; Huda TI; Eakins RA; Diaz MJ; Blanck G
    Viral Immunol; 2023 Dec; 36(10):669-677. PubMed ID: 38052065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TCR CDR3-antigen chemical complementarity associated with poor ovarian cancer outcomes: A vestigial immune response to early cancer antigens?
    Barker VR; Varkhedi M; Patel DN; Hsiang M; Chobrutskiy A; Chobrutskiy BI; Blanck G
    Am J Reprod Immunol; 2023 Jan; 89(1):e13639. PubMed ID: 36317868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGL CDR3 Hydropathy and Antigen Chemical Complementarity Associated with Greater Disease-Free Survival in Lung Adenocarcinoma: Implications for Gender Disparities.
    Charkowick SV; Huda TI; Patel DN; Yeagley M; Arturo JF; Cios KJ; Gozlan EC; Chobrutskiy A; Chobrutskiy BI; Blanck G
    Biochem Genet; 2024 Feb; 62(1):530-546. PubMed ID: 37392243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRB CDR3 chemical complementarity with HBV epitopes correlates with increased hepatocellular carcinoma, disease-free survival.
    Song JJ; Chobrutskiy A; Chobrutskiy BI; Cios KJ; Huda TI; Eakins RA; Diaz MJ; Blanck G
    J Med Virol; 2023 Aug; 95(8):e29043. PubMed ID: 37621059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical features of melanoma tumor resident TRG CDR3s associated with better survival probabilities.
    Agnila DRL; Huda TI; Eakins RA; Patel DN; Hsiang M; Chobrutskiy A; Chobrutskiy BI; Blanck G
    Melanoma Res; 2023 Aug; 33(4):275-282. PubMed ID: 37222076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma.
    Chobrutskiy BI; Yeagley M; Tipping P; Zaman S; Diviney A; Patel DN; Falasiri S; Uversky VN; Blanck G
    Oncogene; 2020 Feb; 39(8):1773-1783. PubMed ID: 31740784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical Complementarity of Breast Cancer Resident, T-Cell Receptor CDR3 Domains and the Cancer Antigen, ARMC3, is Associated With Higher Levels of Survival and Granzyme Expression.
    Pakasticali N; Chobrutskiy A; Patel DN; Hsiang M; Zaman S; Cios KJ; Blanck G; Chobrutskiy BI
    Cancer Inform; 2023; 22():11769351231177269. PubMed ID: 37313373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity.
    Eakins RA; Chobrutskiy A; Teer JK; Patel DN; Hsiang M; Huda TI; Zaman S; Sexton WJ; Coppola D; Falasiri S; Blanck G; Chobrutskiy BI
    Mol Immunol; 2022 Oct; 150():58-66. PubMed ID: 35987136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRB CDR3-cancer testis antigen chemical complementarity scoring for identifying productive immune responses in renal cell carcinoma.
    Hudock TR; Barker VR; Manley BJ; Chobrutskiy A; Chobrutskiy BI; Diaz MJ; Song JJ; Blanck G
    Cancer Biomark; 2023; 38(1):103-110. PubMed ID: 37545223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune receptor CDR3 chemical features that preserve sequence information are highly efficient in reflecting survival distinctions: A pan-cancer analysis.
    Mcbreairty BE; Chobrutskiy BI; Chobrutskiy A; Gozlan EC; Diaz MJ; Blanck G
    Biomed Rep; 2022 Aug; 17(2):68. PubMed ID: 35815190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An immunoinformatics assessment of the cancer testis antigen, DDX53, as a potential early esophageal cancer antigen.
    Cheng P; Cios KJ; Varkhedi M; Barker VR; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
    Oncoscience; 2023; 10():59-66. PubMed ID: 37953875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput quantitative assessments of the chemical complementarity of celiac disease-related IGH CDR3s and a gliadin epitope.
    Jain R; Bressler M; Chobrutskiy A; Chobrutskiy BI; Blanck G
    Int Immunol; 2024 Aug; 36(9):465-470. PubMed ID: 38666722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrostatic Complementarities of Glioblastoma-Resident T-Cell Receptors and Cancer Testis Antigens Linked to Poor Outcomes and High Levels of Sphingosine Kinase-2 Expression.
    Arias MA; Cios KJ; Kacsoh DB; Montgomery BE; Song JJ; Patel AR; Chobrutskiy A; Chobrutskiy BI; Blanck G
    Biology (Basel); 2023 Apr; 12(4):. PubMed ID: 37106775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Worse Wilms' Tumor Outcomes Associated With Chemical Complementarity for Multiple T-Cell Receptor CDR3-CMV Epitope Pairs.
    Rigby KL; Diaz MJ; Gozlan EC; Kacsoh DB; Song JJ; Hudock TR; Chobrutskiy A; Chobrutskiy BI; Blanck G
    Cancer Genomics Proteomics; 2024; 21(5):439-447. PubMed ID: 39191494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.